(-)-CarveolCAS# 99-48-9 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 99-48-9 | SDF | Download SDF |
| PubChem ID | 7438 | Appearance | Oil |
| Formula | C10H16O | M.Wt | 152.2 |
| Type of Compound | Monoterpenoids | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | 2-methyl-5-prop-1-en-2-ylcyclohex-2-en-1-ol | ||
| SMILES | CC1=CCC(CC1O)C(=C)C | ||
| Standard InChIKey | BAVONGHXFVOKBV-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C10H16O/c1-7(2)9-5-4-8(3)10(11)6-9/h4,9-11H,1,5-6H2,2-3H3 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Reference standards. | |||||
(-)-Carveol Dilution Calculator
(-)-Carveol Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 6.5703 mL | 32.8515 mL | 65.703 mL | 131.406 mL | 164.2576 mL |
| 5 mM | 1.3141 mL | 6.5703 mL | 13.1406 mL | 26.2812 mL | 32.8515 mL |
| 10 mM | 0.657 mL | 3.2852 mL | 6.5703 mL | 13.1406 mL | 16.4258 mL |
| 50 mM | 0.1314 mL | 0.657 mL | 1.3141 mL | 2.6281 mL | 3.2852 mL |
| 100 mM | 0.0657 mL | 0.3285 mL | 0.657 mL | 1.3141 mL | 1.6426 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Sempervirine nitrate
Catalog No.:BCN0115
CAS No.:17994-15-9
- (+)-Isocorydine hydrochloride
Catalog No.:BCN0114
CAS No.:13552-72-2
- alpha-Pinene oxide
Catalog No.:BCN0113
CAS No.:1686-14-2
- Dehydroascorbic acid
Catalog No.:BCN0112
CAS No.:490-83-5
- Eupatorin-5-methylether
Catalog No.:BCN0111
CAS No.:21764-09-0
- Furfuryl acetate
Catalog No.:BCN0110
CAS No.:623-17-6
- DL-Threonine
Catalog No.:BCN0109
CAS No.:80-68-2
- 3-Hydroxybenzaldehyde
Catalog No.:BCN0108
CAS No.:100-83-4
- 1-Heptacosanol
Catalog No.:BCN0107
CAS No.:2004-39-9
- Physalien
Catalog No.:BCN0106
CAS No.:144-67-2
- Rigosertib (ON-01910)
Catalog No.:BCN0105
CAS No.:1225497-78-8
- N-Malonyl DL-tryptophan
Catalog No.:BCN0104
CAS No.:3184-74-5
- Tricetinidin chloride
Catalog No.:BCN0117
CAS No.:65618-21-5
- Lactupicrin
Catalog No.:BCN0118
CAS No.:65725-11-3
- VX-702
Catalog No.:BCN0119
CAS No.:479543-46-9
- (+)-Longifolene
Catalog No.:BCN0120
CAS No.:475-20-7
- k-Strophanthoside
Catalog No.:BCN0121
CAS No.:33279-57-1
- Gomisin U
Catalog No.:BCN0122
CAS No.:135095-46-4
- Acetoxyvalerenic acid
Catalog No.:BCN0123
CAS No.:84638-55-1
- Vitexin 2''-glucoside
Catalog No.:BCN0124
CAS No.:61360-94-9
- Fortunellin
Catalog No.:BCN0125
CAS No.:20633-93-6
- 3',5'-Dimethoxy-4'-hydroxyacetophenone
Catalog No.:BCN0126
CAS No.:2478-38-8
- Bacosine
Catalog No.:BCN0127
CAS No.:198014-94-7
- Laudanosine
Catalog No.:BCN0128
CAS No.:1699-51-0
Relaxant Effect of Monoterpene (-)-Carveol on Isolated Human Umbilical Cord Arteries and the Involvement of Ion Channels.[Pubmed:32527034]
Molecules. 2020 Jun 9;25(11). pii: molecules25112681.
Carveol is a monoterpene present in the structure of many plant products. It has a variety of biological activities: antioxidant, anticancer and vasorelaxation. However, studies investigating the effect of monoterpenoids on human vessels have not yet been described. Thus, the present study aimed to characterize the effect of (-)-Carveol on human umbilical arteries (HUAs). HUA ring preparations were isolated and subjected to isometric tension recordings of umbilical artery smooth muscle contractions. (-)-Carveol exhibited a significant vasorelaxant effect on KCl and 5-HT-induced contractions, obtaining EC50 values of 344.25 +/- 8.4 and 175.82 +/- 4.05 microM, respectively. The participation of calcium channels in the relaxation produced by (-)-Carveol was analyzed using vessels pre-incubated with (-)-Carveol (2000 microM) in a calcium-free medium, where the induction of contractions was abolished. The vasorelaxant effect of (-)-Carveol on HUAs was reduced by tetraethylammonium (TEA), which increased the (-)-Carveol EC50 to 484.87 +/- 6.55 microM. The present study revealed that (-)-Carveol possesses a vasorelaxant activity in HUAs, which was dependent on the opening of calcium and potassium channels. These results pave the way for further studies involving the use of monoterpenoids for the vasodilatation of HUAs. These molecules have the potential to treat diseases such as pre-eclampsia, which is characterized by resistance in umbilical arteries.
Standardised comparison of limonene-derived monoterpenes identifies structural determinants of anti-inflammatory activity.[Pubmed:32350292]
Sci Rep. 2020 Apr 29;10(1):7199.
Mint species are widely used in traditional and conventional medicine as topical analgesics for osteoarthritic pain and for disorders of the gastrointestinal and respiratory tracts which are all associated with chronic inflammation. To identify the structural determinants of anti-inflammatory activity and potency which are required for chemical optimization towards development of new anti-inflammatory drugs, a selected group of monoterpenes especially abundant in mint species was screened by measuring bacterial lipopolysacharide (LPS)-induced nitric oxide (NO) production in murine macrophages. Nine compounds significantly decreased LPS-induced NO production by more than 30%. IC50 values were calculated showing that the order of potency is: (S)-(+)-carvone > (R)-(-)-carvone > (+)-dihydrocarveol > (S)-8-hydroxycarvotanacetone > (R)-8-hydroxycarvotanacetone > (+)-dihydrocarvone > (-)-Carveol > (-)-dihydrocarveol > (S)-(-)-pulegone. Considering the carbon numbering relative to the common precursor, limonene, the presence of an oxygenated group at C6 conjugated to a double bond at C1 and an isopropenyl group and S configuration at C4 are the major chemical features relevant for activity and potency. The most potent compound, (S)-(+)-carvone, significantly decreased the expression of NOS2 and IL-1beta in macrophages and in a cell model of osteoarthritis using primary human chondrocytes. (S)-(+)-carvone may be efficient in halting inflammation-related diseases, like osteoarthritis.
